Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents

Advances in Therapy

Volumn 29, Issue 10, 2012, Pages 874-888

  Whitson, Jess T ^a   Petroll, W Matthew ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Benzalkonium chloride; Bimatoprost; Latanoprost; Ophthalmology; Polyquaternium; Preservative; Prostaglandin analog; Tafluprost; Toxicity; Travoprost

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; LATANOPROST; TAFLUPROST; TRAVOPROST;

CELL ASSAY; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOTOXICITY; EPITHELIUM CELL; EYE TOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; REVIEW;

AMIDES; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CELL SURVIVAL; CELLS, CULTURED; CLOPROSTENOL; EPITHELIAL CELLS; EPITHELIUM, CORNEAL; HUMANS; POLYMERS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC;

EID: 84872098988     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0057-1     Document Type: Review

References (31)

1. American Academy of Ophthalmology. Primary open-angle glaucoma suspect, preferred practice pattern. San Francisco, 2005. Available at: http://www.aao.org/ppp. Accessed Jul 13 2012.
2. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd edition. Savona, Italy: Dogma; 2008.
3. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837-45.
4. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123-8.
5. Brignole-Baudouin F, Riancho L, Liang H, Baudouin C. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res. 2011;36:979-88.
6. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-50.
7. Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008;92:1275-82.
8. Liang H, Baudouin C, Faure MO, Lambert G, Brignole-Baudouin F. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Mol Vis. 2009;15:1690-9.
9. Liang H, Pauly A, Riancho L, Baudouin C, Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a threedimensionalreconstituted corneal epithelium system. Br J Ophthalmol. 2011;95:869-75.
10. Pellinen P, Huhtala A, Tolonen A, Lokkila J, Mäenpää J, Uusitalo H. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr Eye Res. 2012;37:145-54.
11. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25:743-51.
12. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-43.
13. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663-71.
14. Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica. 2002;216:175-9.
15. Guglielminetti E, Barabino S, Monaco M, Mantero S, Rolando M. HLA-DR expression in conjunctival cells after latanoprost. J Ocul Pharmacol Ther. 2002;18:1-9.
16. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147:725-35.
17. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-34.
18. Lumigan (bitmatoproset ophthalmic solution) [package insert]. Irvine, CA: Allergan, Inc.; 2010.
19. Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm. 2008;348:175-8.
20. Robertson DM, Li L, Fisher S, et al. Characterization of growth and differentiation in a telomeraseimmortalized human corneal epithelial cell line. Invest Ophthalmol Vis Sci. 2005;46:470-8.
21. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511-19.
22. Gandolfi S, Paredes T, Goldberg I, et al; Travoprost BAK-Free Clinical Study Group. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol. 2012;22:34-44.
23. Kitazawa Y, Smith P, Sasaki N, Kotake S, Bae K, Iwamoto Y. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubledmasked comparison of safety and efficacy. Eye (Lond). 2011;25:1161-9.
24. Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2010;26:287-92.
25. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost BAC-Free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98-103.
26. Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol. 2010;4:1253-61.
27. Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60-4.
28. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-5.
29. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1-9.
30. Turacli E, Budak K, Kaur A, Mizrak B, Ekinci C. The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol. 1997;21:27-33.
31. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618-21.